Many advanced and useful diagnostics, like speckle strain echocardiography, PoCUS, NGAL or IL-18 assays, and even interventions like TIPS, are unavailable or unaffordable in low- and middle-income regions, where the burden of cirrhosis is highest. This evidence concerns the gene LCN2 and Cirrhosis.